Safety and Convenience of Once-Weekly Somapacitan in Adult GH Deficiency: A 26-Week Randomized, Controlled Trial.

CONCLUSIONS: In this 26-week trial in patients with AGHD, somapacitan was well tolerated and no safety issues were identified. Once-weekly somapacitan was reported to be more convenient than once-daily Norditropin®. PMID: 29500310 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29500310?dopt=Abstract

Source: European Journal of Endocrinology - March 2, 2018 Category: Endocrinology Authors: Johannsson G, Feldt-Rasmussen U, Holme Håkonsson I, Biering H, Rodien P, Tahara S, Toogood AA, Rasmussen MH Tags: Eur J Endocrinol Source Type: research